Prospective Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 14, 2016; 22(46): 10226-10231
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10226
Genotype specific peripheral lipid profile changes with hepatitis C therapy
Mark R Pedersen, Amit Patel, David Backstedt, Myunghan Choi, Anil B Seetharam
Mark R Pedersen, Department of Internal Medicine, Banner University Medical Center, University of Arizona College of Medicine, Phoenix, AZ 85006, United States
Amit Patel, David Backstedt, Department of Gastroenterology, Banner University Medical Center, University of Arizona College of Medicine, Phoenix, AZ 85006, United States
Myunghan Choi, Arizona State University College of Nursing and Health Care Innovation, Phoenix, AZ 85006, United States
Anil B Seetharam, Banner Transplant and Advanced Liver Disease Center, University of Arizona College of Medicine, Phoenix, AZ 85006, United States
Author contributions: Seetharam AB designed the study; Pedersen MR, Patel A and Backstedt D performed the data collection; Choi M analyzed the data; Pedersen MR wrote the paper; and Seetharam AB revised the manuscript for final submission.
Institutional review board statement: This study was reviewed and approved by the Banner University Medical Center - Phoenix Institutional Review Board.
Informed consent statement: The need for informed consent for the prospective study was waived by our institutional review board.
Conflict-of-interest statement: Anil Seetharam has served as a speaker and accepted speaker’s fees for Gilead and Janssen.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Anil B Seetharam, MD, Banner Transplant and Advanced Liver Disease Center, University of Arizona College of Medicine, 1300 N. 12th Street Suite 404, Phoenix, AZ 85006, United States. anil.seetharam@bannerhealth.com
Telephone: +1-602-8397000 Fax: +1-602-8397050
Received: June 23, 2016
Peer-review started: June 24, 2016
First decision: August 29, 2016
Revised: September 27, 2016
Accepted: October 27, 2016
Article in press: October 27, 2016
Published online: December 14, 2016
Processing time: 172 Days and 18.8 Hours
Core Tip

Core tip: Different genotypes of the hepatitis C virus (HCV) are associated with differing levels of hepatic steatosis, with genotype 3 (GT3) having the strongest direct association. In this investigation, change in peripheral lipid panels during direct-acting antiviral therapy were assessed in a large HCV treatment cohort with respect to genotype. Total cholesterol in patients with GT3 increased significantly during treatment compared to other genotypes. Associated steatosis and differing lipid kinetics may influence response rates to direct acting therapy and may also influence genotype specific risks of hepatic and systemic complications.